Skip to main content

Table 1 Baseline characteristics are shown in the cohort, and in patients with NT-proBNP measured, separated by treatment group

From: The role of brain natriuretic peptide in atrial fibrillation: a substudy of the Substrate Modification with Aggressive Blood Pressure Control for Atrial Fibrillation (SMAC-AF) trial

Variable: Overall
(n = 173)
Standard group (n = 75) Aggressive group (n = 78)
NT-proBNP ≥ 280*
(n = 24)
NT-proBNP < 280
(n = 51)
p value NT-proBNP ≥ 280
(n = 25)
NT-proBNP < 280
(n = 53)
p value
Age (years, mean ± SD) 59.7 ± 8.7 62.7 ± 6.8 57.5 ± 9.9 0.02 62.2 ± 7.4 58.7 ± 8.8 0.09
Women n (%) 45 (26.0) 9 (37.5) 12 (23.5) 0.21 10 (40) 9 (17) 0.03
Type of AF n (%):     0.09    0.06
Persistent 74 (42.8) 10 (41.7) 32 (63)   11 (44) 35 (66)  
Paroxysmal 99 (57.2) 14 (58.3) 19 (37.3)   14 (56) 18 (34)  
AF duration (months, mean ± SD) 57.2 ± 71.5 42.2 ± 35.6 65.5 ± 79.8 0.12 67.3 ± 99.8 51.1 ± 58.7 0.52
Systolic Blood Pressure (mmHg, mean ± SD) 142.6 ± 12.0 144.0 ± 16.6 141.5 ± 11.0 0.50 145.5 ± 11.8 141.3 ± 10.7 0.13
Hypertension n (%) 130 (75.0) 20 (83.3) 36 (70.6) 0.24 18 (72.0) 42 (79.3) 0.50
Diabetes n (%) 22 (12.7) 2 (8.3) 7 (13.7) 0.49 3 (12) 8 (15.1) 0.71
CHADS2 n (%):     0.61    0.73
0 39 (22.5) 3 (12.5) 13 (25.5)   7 (28) 11 (20.8)  
1 108 (62.4) 18 (75.0) 31 (60.8)   13 (52) 33 (62.3)  
2 18 (10.4) 2 (8.3) 5 (9.8)   3 (12) 7 (13.2)  
 > 2 8 (4.6) 1 (4.2) 2 (3.9)   2 (8) 2 (3.8)  
LVEF (%, mean ± SD) 58.6 ± 8.2 58.3 ± 9.4 60.1 ± 6.1 0.43 55.9 ± 12.1 59.7 ± 7.6 0.19
  1. Characteristics are compared between those with NT-proBNP ≥ 280 pg/mL and < 280 pg/mL, within each treatment group. The aggressive cohort had a target blood pressure of < 120/80 mmHg, and the standard cohort had a target of < 140/90 mmHg
  2. AF, atrial fibrillation; SBP, systolic blood pressure; LVEF, left ventricular ejection fraction
  3. *pg/mL